Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease
Objective: The study of the benefit of intestinal levodopa/carbidopa infusion(LCIG) in resistant ON-freezing of gait(FOG-ON) that appears after Subthalamic Nucleus Deep Brain Stimulation(NST-DBS) in Parkinson’s…A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson’s disease is safe and may be advantageous
Objective: We describe a case series of 12 patients requiring administration of levodopa-carbidopa intestinal gel (LCIG) who had their tube placed by per-oral image guided…Awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease – Insights from an Indian Parkinson’s Registry
Objective: Food interferes with gastrointestinal absorption of levodopa which requires spacing with meals. Study evaluated how many patient were spacing levodopa correctly, its effect on…Clinical profile of idiopathic Parkinson’s disease in patients admitted to Mohamed VI University Hospital center of Marrakech
Objective: Prevalence studies in different parts of the world have shown that Parkinson's disease is a pathology that has a very important impact in older…A Human Factors Study of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer oral LD/CD into the mouths of patients with PD. The System is…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson’s disease : a large single-center study
Objective: To describe adverse events (AEs) associated with levodopa-carbidopa intestinal gel (LCIG) treatment and the main reasons for treatment discontinuation. We also assessed the effectiveness…Prevalence of Parkinson’s disease and parkinsonism in Kyrgyzstan
Objective: Aim of the study is to determine frequency and overall picture of disease characteristics, evaluation and treatment of patients with Parkinson’s disease (PD) and…Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?
Objective: After more than two years of clinical experience with safinamide we want to retrospectively review its utility as a levodopa saver in our Parkinson's…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 57
- Next Page »